253 related articles for article (PubMed ID: 36056868)
1. Serum Interleukin-6 and Weight Loss in Antiretroviral-naïve and Antiretroviral-treated Patients with HIV/AIDS: Relationships and Predictors.
Adedeji TA; Adedeji NO; Ajeigbe AK; Smith OS; Jeje OA; Fawale MB; Ajose AO; Adebisi SA; Akande AA; Okesina BA
Curr HIV Res; 2022; 20(6):441-456. PubMed ID: 36056868
[TBL] [Abstract][Full Text] [Related]
2. Effects of Highly Active Antiretroviral Therapy on Albuminuria in HIVinfected Persons.
Adedeji TA; Adebisi SA; Adedeji NO
Infect Disord Drug Targets; 2020; 20(3):374-384. PubMed ID: 31389318
[TBL] [Abstract][Full Text] [Related]
3. Switching from zidovudine/lamivudine to tenofovir/emtricitabine improves fat distribution as measured by fat mass ratio.
Martínez E; Ribera E; Clotet B; Estrada V; Sanz J; Berenguer J; Rubio R; Pulido F; Larrousse M; Curran A; Negredo E; Arterburn S; Ferrer P; Álvarez ML
HIV Med; 2015 Jul; 16(6):370-4. PubMed ID: 25496141
[TBL] [Abstract][Full Text] [Related]
4. Superior Effectiveness of Zidovudine Compared With Tenofovir When Combined With Nevirapine-based Antiretroviral Therapy in a Large Nigerian Cohort.
Scarsi KK; Eisen G; Darin KM; Meloni ST; Rawizza HE; Tchetgen Tchetgen EJ; Agbaji OO; Onwujekwe DI; Gashau W; Nkado R; Okonkwo P; Murphy RL; Kanki PJ;
Clin Infect Dis; 2016 Feb; 62(4):512-8. PubMed ID: 26561532
[TBL] [Abstract][Full Text] [Related]
5. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
Gallant JE; DeJesus E; Arribas JR; Pozniak AL; Gazzard B; Campo RE; Lu B; McColl D; Chuck S; Enejosa J; Toole JJ; Cheng AK;
N Engl J Med; 2006 Jan; 354(3):251-60. PubMed ID: 16421366
[TBL] [Abstract][Full Text] [Related]
6. Acquired HIV drug resistance among adults living with HIV receiving first-line antiretroviral therapy in Rwanda: A cross-sectional nationally representative survey.
Musengimana G; Tuyishime E; Kiromera A; Malamba SS; Mulindabigwi A; Habimana MR; Baribwira C; Ribakare M; Habimana SD; DeVos J; Mwesigwa RCN; Kayirangwa E; Semuhore JM; Rwibasira GN; Suthar AB; Remera E
Antivir Ther; 2022 Jun; 27(3):13596535221102690. PubMed ID: 35593031
[TBL] [Abstract][Full Text] [Related]
7. Increased virological failure in naive HIV-1-infected patients taking lamivudine compared with emtricitabine in combination with tenofovir and efavirenz or nevirapine in the Dutch nationwide ATHENA cohort.
Rokx C; Fibriani A; van de Vijver DA; Verbon A; Schutten M; Gras L; Rijnders BJ;
Clin Infect Dis; 2015 Jan; 60(1):143-53. PubMed ID: 25273080
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of tenofovir-containing antiretroviral therapy in women who acquired HIV while enrolled in tenofovir gel prophylaxis trials.
Naicker N; Naidoo A; Werner L; Garrett N; Majola N; Asari V; Baxter C; Grobler A; Karim QA; Karim SSA
Antivir Ther; 2017; 22(4):287-293. PubMed ID: 27835613
[TBL] [Abstract][Full Text] [Related]
9. Highly active antiretroviral therapy and dyslipidemia in people living with HIV/AIDS in Fako Division, South West Region of Cameroon.
Nsagha DS; Weledji EP; Assob NJ; Njunda LA; Tanue EA; Kibu OD; Ayima CW; Ngowe MN
BMC Cardiovasc Disord; 2015 Aug; 15():95. PubMed ID: 26315756
[TBL] [Abstract][Full Text] [Related]
10. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
Cahn P; Madero JS; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man C; Currie A; Underwood M; Tenorio AR; Pappa K; Wynne B; Fettiplace A; Gartland M; Aboud M; Smith K;
Lancet; 2019 Jan; 393(10167):143-155. PubMed ID: 30420123
[TBL] [Abstract][Full Text] [Related]
11. Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir.
Robertson K; Maruff P; Ross LL; Wohl D; Small CB; Edelstein H; Shaefer MS
J Neurovirol; 2019 Feb; 25(1):22-31. PubMed ID: 30298202
[TBL] [Abstract][Full Text] [Related]
12. Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study.
Guaraldi G; Zona S; Orlando G; Carli F; Stentarelli C; Luzi K; Garlassi E; Menozzi M; Bagni P; Adorni F
Clin Drug Investig; 2011 Nov; 31(11):759-67. PubMed ID: 21919542
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.
Brogan AJ; Talbird SE; Cohen C
Value Health; 2011; 14(5):657-64. PubMed ID: 21839403
[TBL] [Abstract][Full Text] [Related]
14. Weight and body shape changes in a treatment-naive population after 6 months of nevirapine-based generic highly active antiretroviral therapy in South India.
Saghayam S; Kumarasamy N; Cecelia AJ; Solomon S; Mayer K; Wanke C
Clin Infect Dis; 2007 Jan; 44(2):295-300. PubMed ID: 17173234
[TBL] [Abstract][Full Text] [Related]
15. Effect of highly active antiretroviral therapy on CD4 count and weight in AIDS patients seen at the UITH, Ilorin.
Olawumi HO; Olatunji PO; Salami AK; Odeigah L; Iseniyi JO
Niger J Clin Pract; 2008 Dec; 11(4):312-5. PubMed ID: 19320401
[TBL] [Abstract][Full Text] [Related]
16. Cardiometabolic risk factors among HIV patients on antiretroviral therapy.
Kiage JN; Heimburger DC; Nyirenda CK; Wellons MF; Bagchi S; Chi BH; Koethe JR; Arnett DK; Kabagambe EK
Lipids Health Dis; 2013 Apr; 12():50. PubMed ID: 23575345
[TBL] [Abstract][Full Text] [Related]
17. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
Spaulding A; Rutherford GW; Siegfried N
Cochrane Database Syst Rev; 2010 Oct; (10):CD008740. PubMed ID: 20927777
[TBL] [Abstract][Full Text] [Related]
18. Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention.
Fowler MG; Qin M; Fiscus SA; Currier JS; Flynn PM; Chipato T; McIntyre J; Gnanashanmugam D; Siberry GK; Coletti AS; Taha TE; Klingman KL; Martinson FE; Owor M; Violari A; Moodley D; Theron GB; Bhosale R; Bobat R; Chi BH; Strehlau R; Mlay P; Loftis AJ; Browning R; Fenton T; Purdue L; Basar M; Shapiro DE; Mofenson LM;
N Engl J Med; 2016 Nov; 375(18):1726-1737. PubMed ID: 27806243
[TBL] [Abstract][Full Text] [Related]
19. Changes in Serum Markers of Inflammation and Endothelial Activation in HIV-Infected Antiretroviral Naive Patients Starting A Treatment with Abacavir-Lamivudine or Tenofovir-Emtricitabine Plus Efavirenz.
Calza L; Magistrelli E; Danese I; Colangeli V; Borderi M; Bon I; Re MC; Mancini R; Conti M; Motta R; Viale P
Curr HIV Res; 2016; 14(1):61-70. PubMed ID: 26531764
[TBL] [Abstract][Full Text] [Related]
20. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
